ORGANIZATION

Wrong Policies Could Drive Investments Out of Japan amid China’s Rise, PhRMA Int’l Advocacy Chief Warns

November 6, 2018
For pharmaceutical companies, Japan has long been a priority market in Asia, but the “wrong type” of policies being rolled out in the country in recent years could change all that, warns Brian Toohey, chief of international advocacy at PhRMA. “The…

To read the full story

ORGANIZATION

Takeda Pharmaceutical CEO Christophe Weber highlighted the importance of gaining a strong foothold in the world’s largest pharma market at…

By Reiji Anasako

While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…

By Yoshinori Sagehashi

Daiichi Sankyo and GlaxoSmithKline recently announced that they have agreed to dissolve their joint venture company, Japan Vaccine. The failure of this model of joint venture between a major Japanese and foreign drug maker in just six years is disappointing.Over…

By Gregory Ng

To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…